• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics General Medicine Classics

The ATLAS trial: ACE inhibitor dosing in chronic heart failure [Classics Series]

byLauren KoandAndrew Cheung, MD MBA
March 6, 2014
in General Medicine Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. When compared to a lower dose, high-dose angiotensin-converting-enzyme inhibitor significantly reduced the risk of hospitalization or death in patients with chronic heart failure

Original Date of Publication: December 7, 1999

Study Rundown: Physicians typically prescribe angiotensin-converting-enzyme (ACE) inhibitors to patients with chronic heart failure in lower doses than have been proven effective by large-scale studies. Nonetheless, research on the comparative benefits of high doses and low doses of ACE inhibitors was severely lacking. The ATLAS trial randomized 3,164 patients to receive low- or high-dose of the ACE inhibitor lisinopril for 29-58 months. This study demonstrated that compared with those in the low-dose group, patients in the high-dose treatment group had a significantly lower risk of death or hospitalization for any reason and additionally, significantly fewer hospitalizations for heart failure. These findings suggest that patients with heart failure due to left ventricular systolic dysfunction should not be maintained on low doses of ACE inhibitor unless they are intolerant of higher doses. Rather, tolerant patients should be placed on a higher dose treatment of ACE inhibitor due to its increased effectiveness as compared to low-dose treatment.

Click to read the study in Circulation

In-Depth [randomized, controlled study]: The ATLAS study, originally published in Circulation in 1999, sought to compare the effect of lisinopril dosage on mortality and morbidity of chronic heart failure patients. The study randomly assigned 3,164 patients with New York Heart Association (NYHA) class II to IV heart failure and an ejection fraction of ≤30% to treatment with either a high-dose (32.5-35 mg daily) or low-dose (2.5-5.0 mg daily) of lisinopril, an ACE inhibitor. The trial was conducted in 287 hospitals across 19 countries. The duration of follow-up ranged from 39 to 58 months.

The trial found that patients randomized to receive high-dose lisinopril experienced a 12% lower risk of hospitalization or death for any reason (P=0.002) and 24% fewer hospitalizations for heart failure (P=0.002) as compared to patients in the low-dose group. Patients in the high-dose group did experience dizziness and renal insufficiency more frequently. However, these side effects did not lead to lower compliance with medication in the high-dose group. Based on the findings of this study, it is suggested that patients with chronic heart failure be treated with the highest tolerable doses of ACE inhibitor.

RELATED REPORTS

Dapagliflozin efficacious and safe in treating heart failure

Interatrial shunt device not effective in patients with symptomatic heart failure

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

© 2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: ACE inhibitorsheart failure
Previous Post

Active video games may improve pediatric weight management programs

Next Post

Casino expansion associated with decreased childhood risk of obesity

RelatedReports

Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin efficacious and safe in treating heart failure

May 13, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Interatrial shunt device not effective in patients with symptomatic heart failure

March 29, 2022
StudyGraphics

#VisualAbstract: Effectiveness of sacubitril-valsartan in post-myocardial infarction management compared to ramipril

February 10, 2022
Patient Basics: Heart Attack (Myocardial Infarction)
Cardiology

Effectiveness of sacubitril-valsartan in post-myocardial infarction management

February 3, 2022
Next Post
Casino expansion associated with decreased childhood risk of obesity

Casino expansion associated with decreased childhood risk of obesity

Radiofrequency catheter ablation effective as first-line therapy for atrial fibrillation [RAAFT-2 trial]

Warfarin beneficial in chronic kidney patients with atrial fibrillation

Home-based depression intervention effective for older African-Americans

Gender differences in mental health after moving from poverty

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Severe actinic keratosis and need for additional treatment are markers for an increased risk of cutaneous squamous cell carcinoma
  • Virtual yoga and meditation intervention may be associated with increased health-related quality of life
  • Wellness Check: Mental Health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.